ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT …
WEB4 days ago · TIGIT inhibitors have long been in a difficult race toward the finish line on the non-small cell lung cancer (NSCLC) track. At the European Society for Medical Oncology (ESMO) Congress 2024, GSK ...
ESMO: GSK, iTeos bring some optimism back to TIGIT
WEB4 days ago · There were signs of a dose-response relationship with the TIGIT drug, with 63.3% ORR with the lowest dose (100mg) rising to 65.6% with the middle (400mg) and 76.7% with the high (1,000mg) compared ...
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
WEB3 days ago · GSK and iTeos Therapeutics revealed data Saturday from the Phase II GALAXIES Lung-201 platform Phase II study, showing that Jemperli and the investigational anti-TIGIT therapy belrestotug elicited promising response rates in patients with non-small cell lung cancer. After at least 5.6 months of follow-up, …
An ESMO Day 1 recap: All eyes on TIGIT - STAT
WEB6 days ago · The news from ESMO: The latest on anti-TIGIT data, a PD-(L)1 injection, and more. The group’s leaders also weigh in on ways to protect the oncology workforce. Manage alerts for this article;
Roche’s surprise study results spur new optimism for TIGIT drugs
WEBAug 23, 2023 · The company is testing a drug that pairs Keytruda with a TIGIT inhibitor in a variety of tumor types. Roche, meanwhile, has an extensive development program underway for tiragolumab. Tests are ongoing or planned in tumors of …
Roche nabs breakthrough tag for TIGIT cancer immunotherapy
WEB6 days ago · Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA.
Roche racks up phase 3 TIGIT win but trial design leaves doubts
WEBJan 17, 2024 · Roche has bagged a phase 3 win in TIGIT. But the victory falls short of being a clear-cut endorsement of the mechanism, with the use of a comparator that is no longer the standard of care ...
Roche's accidental data boosts hopes for anti-TIGIT therapy - STAT
WEBAug 23, 2023 · Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small ...
Anti-TIGIT antibody improves PD-L1 blockade through myeloid …
WEBFeb 28, 2024 · Here, in a clinical biomarker analysis of anti-TIGIT and anti-PD- (L)1 antibody combination immunotherapy, coupled with preclinical exploration, we identify a mechanism of action for...
Targeting TIGIT in Non–Small Cell Lung Cancer - ASCO Daily News
WEBJun 23, 2022 · Combining PD-1/PD-L1 inhibitors, the standard of care, with anti-TIGIT immunotherapy shows promise as a way to leverage the host immune system and deliver durable disease control to more patients with stage IV non–small cell lung cancer.
- Some results have been removed
Skip to content